If you have had a stroke, you know the worry that often lingers afterward. The weeks right after are when another one is most likely to hit.
Many survivors spend years asking whether they are on the right medicine.
On November 9, 2026, the US Food and Drug Administration approved asundexian, sold as Sunharbo by Bayer.
It is a once-daily 50 mg pill for adults who have just had a certain kind of mild-to-moderate ischemic stroke or a high-risk transient ischemic attack.
Also read: Researchers find that BMI may misclassify obesity risk in thousands of adults
In a phase 3 trial of 12,327 patients, the pill cut the risk of another ischemic stroke by 26 percent compared with placebo. It is the first drug in a new class, called factor XIa inhibitors, cleared for stroke prevention.
The pill is taken on top of standard antiplatelet therapy such as aspirin, not instead of it. It is not approved for people whose stroke risk comes from atrial fibrillation.
What a factor XIa inhibitor actually does
Older blood thinners can lower stroke risk, but they also raise the chance of bleeding.
That trade-off is often the hardest conversation stroke patients and their doctors have.
Also read: Signs your winter fatigue could actually be seasonal depression
Asundexian works through a different step in the clotting process, called factor XIa.
Researchers have tried for years to design a drug that blocks a specific kind of clot formation without the bleeding risk that comes with classic blood thinners.
What the trial found
The pivotal OCEANIC-STROKE trial, published in the New England Journal of Medicine, randomized 12,327 adults within 72 hours of their stroke or mini-stroke. Half received asundexian, half placebo, both on top of antiplatelet therapy.
Over a median of 14.2 months, 6.2 percent of patients on asundexian had another ischemic stroke. On placebo, it was 8.4 percent.
Also read: Scientists reveal how many steps you really need each day based on your age
Major bleeding was rare in both groups, 1.9 percent with asundexian and 1.7 percent with placebo, and the difference was not statistically significant. Gastrointestinal bleeding happened more often on the drug.
Bleeding risk was also higher in people over 75, and in the first 90 days of treatment. Diarrhea was the most common side effect.
Who is the drug for?
The approval is for adults who have just had a mild-to-moderate ischemic stroke caused by something other than the heart, or a high-risk mini-stroke. That is the stroke type doctors call noncardioembolic.
If that is you or someone you care for, Sunharbo is now a treatment your neurologist can consider adding to your usual antiplatelet pill.
Also read: Taking Ozempic or Wegovy? The FDA just added a vision-loss warning to the label
Whether to switch or add is a conversation for your clinician, who knows your bleeding history and your other medicines.
Every year more than 795,000 people in the United States have a stroke, according to the Centers for Disease Control and Prevention.
Nearly 1 in 4 of those strokes happens to someone who has already had one.
Sunharbo is available in the United States as a 50 mg tablet taken once a day.
Also read: Five breathing techniques that may calm anxiety in just a few minutes
This article is made and published by Ida-Marie Palm Varbæk, who may have used AI in the preparation.
